ARCH Venture Partners is an American venture capital firm that primarily invests in companies in the biotechnology industry, as well as in other industries such as semiconductors and technology. The firm was initially created by the University of Chicago and the Argonne National Laboratory to commercialize their technology, and it has since become an independent firm with a focus on investing in transformative and bold ideas.

ARCH Venture Partners

16VC is a venture capital firm investing in early-stage companies across all sectors.

16VC

35 North Ventures is an investment fund that follows an analysis-driven approach to identify and structure equity portfolios in early-stage companies, focusing on enhancing returns through diversification.

35 North Ventures

Alpview Capital focuses on investment opportunities related to technology-driven innovation, specializing in early and mid-term venture capital as well as heavy vertical industry investment. It seeks entrepreneurial teams with deep market insight and strategic determination.

Alpview Capital

Early stage venture firm focused on life science discoveries to prevent, detect and cure disease.

Alnylam Pharmaceuticals

Beam Therapeutics

Bluebird Bio

Prime Medicine

Quanterix

Resilience

Codiak Biosciences

Twist Bioscience

UNITY Biotechnology

VBI Vaccines

Verve Therapeutics

Vir Biotechnology

Gossamer Bio

Grail

Homology Medicines

Juno Therapeutics

Karuna Therapeutics

Kura Oncology

SAGE Therapeutics

Sana Biotechnology

Denali Therapeutics

EQRx

Erasca

Lyell Immunopharma

Illumina

Fate Therapeutics

Scholar Rock

Metric
Company Name	ARCH Venture Partners	16	35	Alpview Capital
Symbol
MSH ID	COM:ARCHVENTURE	CO:16VC	COM:35NORTHVENTURES	COM:ALPVIEWCAPITAL
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance
Industry	Venture Capital	Venture Capital	Venture Capital	Venture Capital
Country	US	US	US	CN
Stage
Employee Count	60
Website	archventure.com	16vc.co	35northventures.com	alpviewcapital.com
LinkedIn	avpvc		35northventures	alpviewcapital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			187
Web Traffic Growth			3.07
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	14.01
28-Day Growth Score	20.03
90-Day Growth Score	43.06
365-Day Growth Score	43.21

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ARCHVENTURE

ARCH Venture Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue